An external evaluation of the JA after the second year - including the JA process, output and outcome/impact indicators for monitoring and reporting on the progress of implementation of the JA as per the JA agreement.




Development of, based on the sustainability plan, a roadmap on how to integrate deliverables and results of the Joint Action into national policies and action plans and support the review of the national medical specialty guidelines in the selected pilot countries. M12, M18, M24


Regular updtes of the project website and knowledge sharing component (hosting and/or linking of/to best practices, tools and relevant material) Updates are planned to happen annually (M12, M24, M36)


Information package on innovative testing activities and integrated approaches to testing and linkage to care for European testing week participants and other organisations involved in testing of key populations


Consensus recommendations for collection and integration of CBVCTs’ and health care settings’ testing and linkage to care data for HIV, STIs and viral hepatitis into national surveillance and M&E systems


Technical report on improved use of Partner Notification. It will take point of departure in the recommendations made by ECDC (2013) on implementation of partner notification in Europe, and recommendations on policy changes will be addressed as part of WP 4pilot interventions. TB is different in terms of risk of acquisition from the other diseases. However some vulnerable populations at risk for TB are also at risk for HIV, Hepatitis and STIs. Thus this Work Package will look at best-practice across the four diseases, and ways to combine, Partner Notification and contact tracing experiences and best- practice.


Plan, conduct and evaluate 3 regional workshops, in year 2 and 3, to implement capacity building of national stakeholders (CSOs, health care professionals, public health care agencies and invited relevant experts) and training of trainers activities for JA partners.
